7 results about "Pain disorder" patented technology

This invention provides a polypeptide and its applications. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1 or SE ID NO: 2; the 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid; the 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine; the 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine; and the 29th amino acid in the amino acid sequence of the polypeptide is selected from isoleucine, leucine, and tryptophan. The polypeptide provided by this invention has good analgesic function and can selectively inhibit the activation of Nav1.7 channels, thereby inhibiting pain, which has extremely important clinical significance for pain disorders.

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising administration of a pharmaceutically acceptable formulation comprising a glycolysis inhibitor.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Disclosed are compounds having the formula (I), or an enantiomer, diastereomer, tautomer or atropisomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, A, and n are defined herein. Also disclosed are methods of making such compounds, as well as pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of inflammatory disorders, allergic disorders, skin disorders, mast cell disorders, pain disorders, and pruritus disorders. (I)

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.

The disclosure relates to the field of diseases caused by a lowered synaptic inhibition, preferably those that are caused by a diminished activity of the potassium (K) / chloride (Cl) Cotransporter 2 (KCC2). The disclosure involves oligonucleotides and the use thereof in RNA editing methods in targeting a variety of target adenosines in the human SLC12A5 transcript molecule that encodes KCC2. The transcript molecule is edited such that the resulting KCC2 protein has a gain-of-function and / or different function, for example reduced autoinhibition. The disclosure relates to oligonucleotides and their use in the treatment of neurodevelopment disorders, neuropsychiatric disorders, chronic pain disorders, and / or epilepsy.